DONGWHA PHARM.CO.,LTD
Financials
Valuation Metrics
DONGWHA PHARM.CO.,LTD's Market Cap is ₩1466B. At end of 2025 it was ₩1746B. Ranked #981 of 2,405 in KR market (top 41%), #497 of 778 on KOSPI (top 64%), #116 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 146.64B KRW | KR#981/2,405 Sec#116/231 |
| Revenue | 513.24B KRW | KR#613/2,405 Sec#31/231 |
| Net Income | 14.62B KRW | KR#827/2,405 Sec#55/231 |
| Total Assets | 653.67B KRW | KR#643/2,405 Sec#35/231 |
| Net Assets | 415.47B KRW | KR#583/2,405 Sec#35/231 |
| Employees | 824 | KR#303/2,405 Sec#25/231 |
| Value | ||
| P/E | 9.97x | KR#869/2,405 Sec#43/231 |
| P/B | 0.35x | KR#527/2,405 Sec#18/231 |
| P/S | 0.28x | KR#604/2,405 Sec#15/231 |
| EV/EBITDA | 12.26x | KR#778/2,405 Sec#41/231 |
| FCF Yield | -25.56% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 3.52% | KR#1,281/2,405 Sec#88/231 |
| ROA | 2.24% | KR#1,174/2,405 Sec#87/231 |
| Op. Margin | 3.68% | KR#1,137/2,405 Sec#82/231 |
| Revenue Growth | 6.59% | KR#1,094/2,405 Sec#108/231 |
| Financial Health | ||
| Debt Ratio | 57.34% | KR#1,057/2,405 Sec#123/231 |
| Total Debt | 107.12B KRW | KR#701/2,405 Sec#43/231 |
| FCF | -37.48B KRW | KR#2,016/2,405 Sec#199/231 |
| Cash | 22.05B KRW | KR#1,193/2,405 Sec#82/231 |
| Current Ratio | 1.22x | KR#1,471/2,405 Sec#153/231 |
| Net Debt/EBITDA | 4.50x | KR#999/2,405 Sec#73/231 |
| Dividend | ||
| Div. Yield | 1.28% | KR#1,088/2,405 Sec#61/231 |
| Div. Growth | -63.89% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -16.61% | KR#1,024/2,405 Sec#65/231 |
| 1M Return | 1.95% | KR#242/2,405 Sec#27/231 |
| From 52W High | -30.95% | KR#442/2,405 Sec#28/231 |
| 1Y MDD | -31.78% | KR#292/2,405 Sec#19/231 |
| Trading | ||
| Volume | 76,005 shares | KR#746/2,405 Sec#78/231 |
| Trading Value | 393.5M KRW | KR#879/2,405 Sec#97/231 |
| Foreign Own. | 3.22% | KR#1,220/2,405 Sec#112/231 |
| Per Share | ||
| EPS | 524 KRW | KR#977/2,405 Sec#70/231 |
| BPS | 14,874 KRW | KR#706/2,405 Sec#44/231 |
Company Info
Established in 1897 and listed on the Stock Market in 1976, this pharmaceutical company acquired medical device manufacturer Medyssey in 2020 and Vietnamese pharmaceutical distribution chain TS Care in 2023. It specializes in manufacturing and selling pharmaceuticals, active pharmaceutical ingredients, quasi-drugs, and medical devices, also producing health functional foods. The company targets sustainable growth by addressing an aging society, improving economic standards, and developing biotech new drugs for intractable diseases. Dong Wha Pharmaceutical is headquartered in Jung-gu, Seoul Metropolitan City.